Phosphinate based inhibitors of matrix metalloproteases
CA 2260898 C · Owner: Pfizer Limited · Inventors: Reiter, Lawrence Alan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound of the formula (I) wherein R1 R2, R3, R4, R5, R6 and Ar are as , defined above useful in the treatment of a condition selected from the group consisting of arthritis, cancer, synergy with cytotoxic anticancer agents tissue ulceration, macular degeneration restenosis, periodontal disease, epidermolysis bullosa scleritis, in combination with standard NSAID'S and analgesics and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 30, 1997 and granted May 14, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 30, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 30, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.